In a major breakthrough development, DABUR India Limited has completed a large scale, multicentric, clinical study on their premium Ayurvedic healthcare product– Dabur Chyawanprash.

This clinical study evaluated the beneficial role of Dabur Chyawanprash as a prophylaxis remedy for COVID-19 infection.

This study was conducted following applicable GCP guidelines, was approved by multiple Institutional Ethics Committees and was registered with the Clinical Trials Registry of India which is a portal of ICMR.

Subjects were enrolled in the study after taking informed consent from all the study participants.

The findings of the study reveal that regular use of Dabur Chyawanprash reduced the risk of COVID-19 infection by up to 12 times in comparison to the control group which was not consuming Chyawanprash.

It was also noted that with regular usage of Dabur Chyawanprash, there was up to 6 times lesser severity of COVID 19 infections when compared to subjects in the control group.

ALSO READ | COVID-19 Vaccine: 53% Indians Unsure About Taking It

The severity of COVID-19 was assessed as per ordinal scale published by the WHO (World Health Organization) for COVID-19.

Commenting on the revelations, Prashant Agarwal, Marketing Head - Health Supplements, Dabur India Limited said, “In the era of COVID-19, strong immunity has become the primary need of every individual more than ever before."

"Dabur Chyawanprash, with the power of more than 40 Ayurvedic herbs like Amla, Ashwagandha, Giloy etc., has always stood for boosting immunity to fight illnesses," he added.

"Now, with the findings of the current clinical study which was conducted following GCP and ICMR ethical guidelines coming in, we are confident of helping the nation in this steep battle against COVID-19,” he further said.

“Dabur has been relentlessly pursuing the cause of providing Ayurveda based solutions backed by modern science," Dr Arun Gupta, Dabur India Limited’s Head - Scientific Affairs.

"Dabur Chyawanprash has earlier been studied scientifically in various studies for its beneficial role in boosting immunity," he added.

"The beneficial effects of this study probably are due to the proven effects of Chyawanprash on immunity," he further said.

"The investigational team for this current study included Doctors and Scientists from both Ayurveda as well as the modern system of medicine," Dr Gupta further said.

"Dabur has submitted the results of the study to the concerned ethics committees as well as to the Ministry of AYUSH," he further said.

This open-label, randomized, controlled, multicentric clinical study was conducted on healthy volunteers across five different Ayurveda Institutions including Jaipur, Mumbai, Pune and two sites at Vadodara.

In one group, the subject consumed one teaspoonful of Dabur Chyawanprash two times a day for a period of 3 months.

A total of 696 subjects completed the study, out of which 351 subjects were in Chyawanprash group and 345 subjects were in the control group that did not take Chyawanprash.

This clinical study revealed Dabur Chyawanprash to be a good prophylaxis remedy for healthy individuals for its beneficial effects in the prevention of COVID-19 infection.